Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.
Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, León CC, Sierra Sánchez JF, Prieto MDL, Porcuna NC, Mochón MDO, Macías J, de la Iglesia Salgado A, Granger JR, Fernández MD, Lozano IG, Ramírez ER, Rivero A, Del Carmen Lozano Domínguez M, Viciana I, Montemayor JCG, García FG. Arboledas JCA, et al. Among authors: perez ab. Diagn Microbiol Infect Dis. 2017 Sep;89(1):29-34. doi: 10.1016/j.diagmicrobio.2017.06.006. Epub 2017 Jun 17. Diagn Microbiol Infect Dis. 2017. PMID: 28669680
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Pineda JA, Rivero-Juárez A, de Los Santos I, Collado A, Merino D, Morano-Amado LE, Ríos MJ, Pérez-Pérez M, Téllez F, Palacios R, Pérez AB, Mancebo M, Rivero A, Macías J. Pineda JA, et al. Among authors: perez perez m, perez ab. HIV Clin Trials. 2018 Feb;19(1):23-30. doi: 10.1080/15284336.2018.1436637. Epub 2018 Feb 15. HIV Clin Trials. 2018. PMID: 29447085 Clinical Trial.
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F. Cuypers L, et al. Among authors: perez ab. PLoS One. 2018 Jul 25;13(7):e0201268. doi: 10.1371/journal.pone.0201268. eCollection 2018. PLoS One. 2018. PMID: 30044871 Free PMC article.
Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain.
Pérez AB, Vrancken B, Chueca N, Aguilera A, Reina G, García-Del Toro M, Vera F, Von Wichman MA, Arenas JI, Téllez F, Pineda JA, Omar M, Bernal E, Rivero-Juárez A, Fernández-Fuertes E, de la Iglesia A, Pascasio JM, Lemey P, Garcia F, Cuypers L. Pérez AB, et al. Euro Surveill. 2019 Feb;24(9):1800227. doi: 10.2807/1560-7917.ES.2019.24.9.1800227. Euro Surveill. 2019. PMID: 30862327 Free PMC article.
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-Gallego MJ, Rosales-Zábal JM, García F; GEHEP-004 Study Group. Pérez AB, et al. J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279901
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Pérez AB, et al. PLoS One. 2019 Aug 30;14(8):e0221231. doi: 10.1371/journal.pone.0221231. eCollection 2019. PLoS One. 2019. PMID: 31469856 Free PMC article.
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Téllez F, Bernal E, Rincón P, Von Wichman MA, Fuentes A, Vera F, Rivero-Juárez A, Jiménez M, Vandamme AM, García F. Vrancken B, et al. Among authors: perez ab. J Hepatol. 2019 Dec;71(6):1270-1272. doi: 10.1016/j.jhep.2019.08.010. Epub 2019 Oct 1. J Hepatol. 2019. PMID: 31585736 Free article. No abstract available.
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Dietz J, et al. J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33220331
131 results